L-R: Prof Chris Hayward, Dr Paul Jansz and Dr Daniel Timms. Image credit: Victor Chang Cardiac Research Institute
L-R: Prof Vice-Chancellor Mike Ryan, Prof Chris Hayward, Dr Paul Jansz and Dr Daniel Timms. Image credit: Artificial Heart Frontiers Program (AHFP)
Last week, the world witnessed an extraordinary milestone in Mechanical Circulatory Support (MCS) – the successful implantation of BiVACOR Total Artificial Heart (TAH) in a patient in Australia. Even more remarkably, the patient thrived for 100+ days while awaiting a donor heart. This groundbreaking achievement has made global headlines, underscoring the transformative potential of BiVACOR’s technology in the future of heart failure treatment.
At Hydrix, we are proud to have played a role in BiVACOR’s journey over the past years, particularly in the development of the heart’s controller, a critical component that enables its function.
More broadly, for over a decade, we have been at the forefront of advancing life-saving MCS technologies, including artificial hearts and ventricular assist devices (VADs). Working with pioneering innovators across the world, we specialize in translating bold ideas into reliable, clinically impactful solutions that change lives.
Congratulations to BiVACOR and the clinical team on this historic achievement! We look forward to seeing how their achievements continue to shape the future of heart failure treatment worldwide.
Read more about this milestone:
AFR: OneVentures-backed artificial heart start-up raising $100M
ABC News: Sydney hospital performs Australia’s first artificial heart implant
Monash University: Australia’s first durable total artificial heart implant a success
